(3S)-N-(Boc-L-亮氨酸)-1,2,3,4-四氢异喹啉-3-羧酸 | 1036718-13-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (3S)-N-(Boc-L-亮氨酸)-1,2,3,4-四氢异喹啉-3-羧酸
• 英文名称: (3S)-N-(Boc-L-leucyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
• 英文别名: (3S)-N-(Boc-L-leucinyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid；Boc-Leu-Tic-OH；(3S)-2-[(2S)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
• CAS: 1036718-13-4
• 化学式: C₂₁H₃₀N₂O₅
• 分子量: 390.48
• InChiKey: PXAKJOYOAGNQIQ-IRXDYDNUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3S)-N-(Boc-L-亮氨酸)-1,2,3,4-四氢异喹啉-3-羧酸 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 以89%的产率得到(3S)-N-(L-leucyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
  参考文献：
  名称：

  (3S)-N-(l-Aminoacyl)-1,2,3,4-tetrahydroisoquinolines, a class of novel antithrombotic agents: Synthesis, bioassay, 3D QSAR, and ADME analysis

  摘要：

  To increase antithrombotic activity, 3S-tetrahydroisoquinoline-3-carboxylic acid (1) was modified with natural amino acids to form 19 novel dipeptide analogs, 3S-tetrahydroisoquinoline-3-carboxyamino acids (5a-s), targeting the intestinal peptide transport system. In vitro assay of 5a-s indicated that their potencies for inhibiting adenosine diphosphate (ADP), arachidonic acid (AA), platelet-activating factor (PAF), and thrombin (TH)-induced platelet aggregations were higher than that of 1. Additionally, in vivo assay of 5a-s indicated that their potencies for inhibiting thrombogenesis in rats were also higher than that of 1. Among the candidates, 5h with Ser attachment showed the most impressive features for further development. According to molecular field analysis based Cerius(2) QSAR module, two equations (r, 0.961 and 0.988) correlating the structures with both in vitro and in vivo activities of 5a-s were established. ADMET calculations predict higher intestinal absorption for compounds 5a-s. Further investigation with 5h as a lead compound is underway. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.09.019
• 作为产物：
  描述：

  (3S)-N-(Boc-L-leucinyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl ester 在 水 、 sodium hydroxide 、 potassium hydrogensulfate 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 以96%的产率得到(3S)-N-(Boc-L-亮氨酸)-1,2,3,4-四氢异喹啉-3-羧酸
  参考文献：
  名称：

  2,3-Diamino acid modifying 3S-tetrahydroisoquinoline-3-carboxylic acids: Leading to a class of novel agents with highly unfolded conformation, selective in vitro anti-platelet aggregation and potent in vivo anti-thrombotic activity

  摘要：

  In the preparation of anti-thrombotic agents the 2- and 3-positions of 3S-tetra-hydroisoquinoline-3-carboxylic acid (THIQA) were simultaneously modified with amino acids to form 20 novel N-(3S-N-amino-acyl-1,2,3,4-tetrahydroisoquinoline-3-carbonyl) amino acids (8a-t). On an in vitro platelet aggregation model 8a-t selectively inhibit ADP-induced platelet aggregation and their IC50 values are leas than 3.5 nM. On an extracorporeal circulation of arterioveinos cannula model of rats both orally and intraveously effective doses of 8a-t are less than 30 nmol/kg. Cerius(2) based stereoview of explores 8a-t having highly unfolded conformation. 3D QSAR analysis gives the importance of the unfolded conformation to high in vitro anti-platelet aggregation and in vivo anti-thrombotic potency rational understanding. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.01.009

文献信息

• 2,3-Diamino acid modifying 3S-tetrahydroisoquinoline-3-carboxylic acids: Leading to a class of novel agents with highly unfolded conformation, selective in vitro anti-platelet aggregation and potent in vivo anti-thrombotic activity
  作者：Xiaoyi Zhang、Wei Wang、Shenling Cheng、Ming Zhao、Meiqing Zheng、Heng Wei Chang、Jianhui Wu、Shiqi Peng

  DOI：10.1016/j.bmc.2010.01.009

  日期：2010.2

  In the preparation of anti-thrombotic agents the 2- and 3-positions of 3S-tetra-hydroisoquinoline-3-carboxylic acid (THIQA) were simultaneously modified with amino acids to form 20 novel N-(3S-N-amino-acyl-1,2,3,4-tetrahydroisoquinoline-3-carbonyl) amino acids (8a-t). On an in vitro platelet aggregation model 8a-t selectively inhibit ADP-induced platelet aggregation and their IC50 values are leas than 3.5 nM. On an extracorporeal circulation of arterioveinos cannula model of rats both orally and intraveously effective doses of 8a-t are less than 30 nmol/kg. Cerius(2) based stereoview of explores 8a-t having highly unfolded conformation. 3D QSAR analysis gives the importance of the unfolded conformation to high in vitro anti-platelet aggregation and in vivo anti-thrombotic potency rational understanding. (C) 2010 Elsevier Ltd. All rights reserved.
• (3S)-N-(l-Aminoacyl)-1,2,3,4-tetrahydroisoquinolines, a class of novel antithrombotic agents: Synthesis, bioassay, 3D QSAR, and ADME analysis
  作者：Meiqing Zheng、Xiaoyi Zhang、Ming Zhao、Heng Wei Chang、Wei Wang、Yuji Wang、Shiqi Peng

  DOI：10.1016/j.bmc.2008.09.019

  日期：2008.11

  To increase antithrombotic activity, 3S-tetrahydroisoquinoline-3-carboxylic acid (1) was modified with natural amino acids to form 19 novel dipeptide analogs, 3S-tetrahydroisoquinoline-3-carboxyamino acids (5a-s), targeting the intestinal peptide transport system. In vitro assay of 5a-s indicated that their potencies for inhibiting adenosine diphosphate (ADP), arachidonic acid (AA), platelet-activating factor (PAF), and thrombin (TH)-induced platelet aggregations were higher than that of 1. Additionally, in vivo assay of 5a-s indicated that their potencies for inhibiting thrombogenesis in rats were also higher than that of 1. Among the candidates, 5h with Ser attachment showed the most impressive features for further development. According to molecular field analysis based Cerius(2) QSAR module, two equations (r, 0.961 and 0.988) correlating the structures with both in vitro and in vivo activities of 5a-s were established. ADMET calculations predict higher intestinal absorption for compounds 5a-s. Further investigation with 5h as a lead compound is underway. (C) 2008 Elsevier Ltd. All rights reserved.